A case report of a patient with plasmacytoid urothelial cancer with significant response to HER2-targeting therapy and enfortumab vedotin.
Urothelial carcinoma
biomarkers
bladder cancer
plasmacytoid variant
Journal
American journal of clinical and experimental urology
ISSN: 2330-1910
Titre abrégé: Am J Clin Exp Urol
Pays: United States
ID NLM: 101634566
Informations de publication
Date de publication:
2021
2021
Historique:
received:
09
05
2021
accepted:
29
06
2021
entrez:
19
11
2021
pubmed:
20
11
2021
medline:
20
11
2021
Statut:
epublish
Résumé
In this case report, we present a patient with the rare plasmacytoid variant of urothelial cancer. Notable elements of his course include: complete response to neoadjuvant paclitaxel, gemcitabine, cisplatin, development of metastatic disease to the rectum, sustained disease control with dual HER2 targeting therapy, and subsequent complete response to enfortumab vedotin. Plasmacytoid urothelial cancer accounts for just 1-3% of all urothelial cancer cases and is associated with more aggressive disease, with a propensity for intra-abdominal spread and poor response to neoadjuvant therapy. Preliminary data indicate that the variant may generally have high levels of HER2 expression. We review the history of HER2 targeting in metastatic urothelial cancer, which has included single-agent as well as combination with chemotherapy; there are ongoing biomarker-based clinical trials. Furthermore, we highlight the complete response to enfortumab vedotin. To date, this is the first report of efficacy for enfortumab vedotin in the plasmacytoid variant.
Types de publication
Case Reports
Langues
eng
Pagination
390-396Informations de copyright
AJCEU Copyright © 2021.
Déclaration de conflit d'intérêts
Research funding to Weill Cornell Medicine from Seagen, Gilead, Janssen, Merck, AstraZeneca. Receipt of honoraria from: Janssen, Seagen, Gilead.
Références
Urology. 2014 May;83(5):1112-6
pubmed: 24582117
Eur J Cancer. 2015 Jan;51(1):45-54
pubmed: 25459391
N Engl J Med. 2021 Mar 25;384(12):1125-1135
pubmed: 33577729
BMC Cancer. 2013 Feb 08;13:71
pubmed: 23394492
Hum Pathol. 2019 Aug;90:27-36
pubmed: 31054897
Urol Oncol. 2014 Aug;32(6):833-8
pubmed: 24954925
J Urol. 2012 Mar;187(3):852-5
pubmed: 22245324
J Clin Oncol. 2007 Jun 1;25(16):2218-24
pubmed: 17538166
N Engl J Med. 2012 Nov 8;367(19):1783-91
pubmed: 23020162
J Clin Oncol. 2019 Oct 10;37(29):2592-2600
pubmed: 31356140
N Engl J Med. 2005 Oct 20;353(16):1673-84
pubmed: 16236738
Eur Urol. 2011 Aug;60(2):350-7
pubmed: 21640482
Clin Cancer Res. 2001 Aug;7(8):2440-7
pubmed: 11489824
Am J Clin Pathol. 2017 May 1;147(5):500-506
pubmed: 28371875
Clin Cancer Res. 2021 Feb 15;27(4):922-927
pubmed: 32962979
J Urol. 2015 Oct;194(4):1120-31
pubmed: 26047983
Eur Urol Focus. 2019 Jan;5(1):104-108
pubmed: 28753857
J Clin Oncol. 2020 Apr 1;38(10):1041-1049
pubmed: 32031899
Bladder Cancer. 2020;6(1):71-81
pubmed: 34109262
Dis Markers. 2016;2016:8463731
pubmed: 27034533
Cancer. 2009 Jul 1;115(13):2881-90
pubmed: 19399906
Nat Genet. 2016 Apr;48(4):356-8
pubmed: 26901067
Cancer Treat Rev. 2015 Sep;41(8):699-706
pubmed: 26138514
Cancer Res. 2016 May 15;76(10):3003-13
pubmed: 27013195
N Engl J Med. 2001 Mar 15;344(11):783-92
pubmed: 11248153
J Clin Oncol. 2017 Jan;35(1):48-55
pubmed: 28034079
J Clin Oncol. 2012 Apr 1;30(10):1107-13
pubmed: 22370319